. 2023 Feb 15;20(4):3439. doi: 10.3390/ijerph20043439

Table 2.

Baseline characteristics of included studies.

Study	Design	Intervention	Cohort	Follow-Up (Months)	VARC-2 Definitions	ROBINS-I
Alvarado T et al., 2021 [19]	SC RCS	Evolut PRO	33	12.0 ± 0.2	yes	moderate
Alvarado T et al., 2021 [19]	SC RCS	Evolut R	50	11.0 ± 0.5	yes	moderate
Dallan LAP et al., 2021 [20]	MC PCS	Evolut PRO	836	12	yes	moderate
Dallan LAP et al., 2021 [20]	MC PCS	Evolut R	5061	12	yes	moderate
Forrest JK et al., 2020 [21]	MC RCS, PM	Evolut PRO	1500	NR	yes	moderate
Forrest JK et al., 2020 [21]	MC RCS, PM	Evolut R	1500	NR	yes	moderate
Hellhammer K et al., 2018 [22]	SC RCS, PM	Evolut PRO	74	1	yes	moderate
Hellhammer K et al., 2018 [22]	SC RCS, PM	Evolut R	148	1	yes	moderate
Kalogeras K et al. (ATLAS) 2020 [23]	MC RCS	Evolut PRO	175	12	yes	moderate
Kalogeras K et al. (ATLAS) 2020 [23]	MC RCS	Evolut R	498	12	yes	moderate
Kroon HG et al., 2021 [24]	SC PCS	Evolut PRO	92	1	yes	moderate
Kroon HG et al., 2021 [24]	SC PCS	Evolut R	160	1	yes	moderate
Loewenstein I et al., 2022 [25]	MC RCS, PM	Evolut PRO	222	1	yes	moderate
Loewenstein I et al., 2022 [25]	MC RCS, PM	Evolut R	213	1	yes	moderate
Modolo R et al., 2020 [26]	MC RCS	Evolut PRO	95	NR	NR	moderate
Modolo R et al., 2020 [26]	MC RCS	Evolut R	295	NR	NR	moderate
Rao G et al., 2019 [27]	SC RCS	Evolut PRO	60	1	yes	moderate
Rao G et al., 2019 [27]	SC RCS	Evolut R	56	1	yes	moderate
Regazzoli D et al., 2019 [28]	MC RCS	Evolut PRO	84	12	yes	moderate
Regazzoli D et al., 2019 [28]	MC RCS	Evolut R	397	12	yes	moderate
Schmidt S et al., 2022 [29]	MC RCS	Evolut PRO	268	NR	yes	moderate
Schmidt S et al., 2022 [29]	MC RCS	Evolut R	546	NR	yes	moderate

SC, single center; MC, multicenter; RCS, retrospective cases series; PCS, prospective cohort study; PM, propensity match; VARC-2, Valve Academic Research Consortium-2; ROBINS-I, risk of bias in non-randomized studies - of intervention; NR, not reported.